# CMP-001 for Relapsed and Refractory Lymphoma

> **NCT03983668** · PHASE1,PHASE2 · TERMINATED · sponsor: **Umar Farooq** · enrollment: 14 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** CMP-001
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03983668
- **Lead sponsor:** Umar Farooq
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-31
- **Primary completion:** 2024-08-23
- **Final completion:** 2025-04-08
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Manufacturing issue with investigational drug
- **Last updated:** 2026-03-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03983668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03983668, "CMP-001 for Relapsed and Refractory Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03983668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*